E

What can we learn from early IO trials?

There are a number of important lessons we can learn from early phase 1 trials. Here are some of them.

November 16, 2018
E

Pinning down potential new opportunities for IL–8 and 4–1BB

What is old is new again - a look at some forgotten oncology targets that are coming back in fashion

November 13, 2018
E

An analysis of Nektar’s latest PIVOT data and pipeline update

Update on PIVOT-02 with nivolumab plus NKTR-214 in 1L metastatic melanoma

November 12, 2018
E

How the microbiota impact response to cancer immunotherapy

The evolving story of how commensal microbiota can affect response to cancer immunotherapy

November 9, 2018
E

New developments in immune escape

Latest news and insights on immune escape mechanisms associated with cancer immunotherapy

November 8, 2018
E

SITC18 Preview and IO curiosities

An extensive round-up of what to expect from SITC18 ahead of the abstract reveal

November 2, 2018